Amplia Therapeutics Ltd (ASX:ATX)'s CEO John Lambert tells Proactive they've completed the design for a Phase 2 clinical trial of its Focal Adhesion Kinase (FAK) inhibitor, AMP945 in newly diagnosed patients receiving first-line therapy for pancreatic cancer. The company plans to initiate patient recruitment at Australian sites in the first quarter of 2022.
Amplia Therapeutics details upcoming Phase 2 pancreatic cancer trial
